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Abstract
Mycoplasma hyopneumoniae is the causative agent of porcine enzootic pneumonia, a chronic and
economically significant respiratory disease that affects swine production worldwide. M. hyopneumoniae
adheres to, and adversely affects the function of ciliated epithelial cells of the respiratory tract, and the
cilium adhesin (P97), is intricately but not exclusively involved in this process. Although binding of
pathogenic bacteria to glycosaminoglycans is a recognised step in pathogenesis, knowledge of
glycosaminoglycan-binding proteins is lacking in M. hyopneumoniae. However, heparin and other sulfated
polysaccharides are known to block the binding of M. hyopneumoniae to purified swine respiratory cilia.
In this study, four regions within the cilium adhesin were examined for their ability to bind heparin. Cilium
adhesin fragments comprising 653 amino acids of the N- terminus and 301 amino acids of the Cterminus (containing two repeat regions, R1 and R2) were cloned and expressed. These fragments bound
heparin in a dose-dependent and saturable manner with physiologically significant binding affinities of
0.27±0.02 µM and 1.89±0.33 µM, respectively. Heparin binding of both fragments was strongly inhibited
by the sulfated polysaccharides fucoidan and mucin but not by chondroitin sulfate B. When the C-terminal
repeat regions R1 and R2 were cloned separately and expressed, heparin-binding activity was lost,
suggesting that both regions are required for heparin binding. The ability of the cilium adhesin to bind
heparin indicates that this molecule plays a multi-functional role in the adherence of M. hyopneumoniae
to host respiratory surfaces and therefore has important implications with respect to the pathogenesis of
this organism.
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Abstract
Mycoplasma hyopneumoniae is the causative agent of porcine enzootic pneumonia, a
chronic and economically significant respiratory disease that affects swine production
worldwide. M. hyopneumoniae adheres to, and adversely affects the function of ciliated
epithelial cells of the respiratory tract, and the cilium adhesin (P97), is intricately but not
exclusively involved in this process. Although binding of pathogenic bacteria to
glycosaminoglycans is a recognised step in pathogenesis, knowledge of
glycosaminoglycan-binding proteins is lacking in M. hyopneumoniae. However, heparin
and other sulfated polysaccharides are known to block the binding of M. hyopneumoniae
to purified swine respiratory cilia. In this study, four regions within the cilium adhesin
were examined for their ability to bind heparin. Cilium adhesin fragments comprising
653 amino acids of the N- terminus and 301 amino acids of the C-terminus (containing
two repeat regions, R1 and R2) were cloned and expressed. These fragments bound
heparin in a dose-dependent and saturable manner with physiologically significant
binding affinities of 0.27±0.02 µM and 1.89±0.33 µM, respectively. Heparin binding of
both fragments was strongly inhibited by the sulfated polysaccharides fucoidan and
mucin but not by chondroitin sulfate B. When the C-terminal repeat regions R1 and R2
were cloned separately and expressed, heparin-binding activity was lost, suggesting that
both regions are required for heparin binding. The ability of the cilium adhesin to bind
heparin indicates that this molecule plays a multi-functional role in the adherence of M.
hyopneumoniae to host respiratory surfaces and therefore has important implications with
respect to the pathogenesis of this organism.
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Introduction
Mycoplasma hyopneumoniae is the aetiological agent of porcine enzootic pneumonia,
a chronic respiratory disease that causes significant economic losses to the swine industry
(30). Infections are established via colonization of porcine respiratory epithelia, a process
initiated by the adherence of bacterial cells to host cilia. Successful colonization results in
ciliostasis and shedding of cilia from the epithelial surface, thereby disrupting the mucociliary escalator and leaving the host susceptible to secondary infections (3, 9).
Studies have shown that the cilium adhesin, P97, is essential for the adherence of M.
hyopneumoniae and the onset of disease (15, 37). The cilium adhesin gene encodes a 126
kDa pre-protein. The full length protein is not present in in vitro grown cells in detectable
amounts due to post-translational processing. A major cleavage event at position 195
generates the functional adhesin (P97) and the N-terminal fragment (P22). P97 is further
cleaved to yield a host of other peptides (10). While the functions of these peptides (apart
from P97) are unknown, proteomic and immunogold studies demonstrate that they
remain associated with the cell surface or the surrounding matrix (10).
Like several other characterized mycoplasma adhesins, P97 contains repetitive
elements within the C-terminal portion of its amino acid sequence (4, 8, 15). P97 contains
two such repeat regions, designated R1 and R2, with R1 (sequence AAKPV/E) being
identified as the cilium binding epitope (16). Size variation in the cilium adhesin protein
of different M. hyopneumoniae strains (95-97 kDa) has been accounted for by differences
in the number of copies of R1, which varies from 9 in the non-adherent J strain, to 15 in
the pathogenic 232 strain (35). A minimum of 8 copies of the R1 repeat are necessary for
cilial binding, but this is not sufficient to confer the ability to adhere in vivo (16, 23).
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These data suggest that there are additional proteins and mechanisms involved in
adherence to host epithelia.
The importance of binding to host extracellular matrix (ECM) components in
initiating pathogenic processes has been well documented. By binding to ECM proteins
such as fibronectin, vitronectin, laminin, and collagen, pathogenic microbes are able to
mediate interactions with host cells (27), and in some cases enhance their invasive
potential (12, 18, 28). Furthermore, it has been demonstrated that many pathogens are
able to recruit exogenous glycosaminoglycans (eg. heparin, heparan sulfate and
chondroitin sulfate B) to their surfaces to facilitate interactions between the pathogen and
host ECM components, which are themselves glycosaminoglycan binding proteins (13,
21, 34). Binding to glycosaminoglycans is also believed to enable pathogenic bacteria to
evade the host immune system (7, 12) and modulate the inflammatory response (13) by
allowing bridging interactions with host chemokines and cytokines. Thus,
glycosaminoglycan-binding proteins are considered to be of central importance to the
infection process.
Previous experiments have revealed that adherence of purified recombinant P97 to
cilia is inhibited by sulfated glycosaminoglycans (15). These findings suggest a possible
interaction between the P97 protein and sulfated glycosaminoglycans which may act as
receptor analogs for the M. hyopneumoniae adhesin (15, 36, 38); however; these studies
did not directly demonstrate such an interaction. Furthermore, the domains within the
cilium adhesin responsible for this interaction were not identified. In this study we
identify regions within the cilium adhesin that interact with the glycosaminoglycan,
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heparin. The ability of M. hyopneumoniae cell surface molecules to bind heparin may
play a significant role in the pathogenesis of this organism.

Materials and Methods
Bacterial strains and plasmids. M. hyopneumoniae strain J (NCTC 10110) was
cultivated to mid-log phase (medium pH range 6.8-7.2) in modified Friis broth at 37°C
on a rotary shaker as described previously (33). The Escherichia coli plasmid expression
and maintenance strains were M15 (pREP4) and JM109 respectively, and were grown in
Luria-Bertani (LB) medium (31) at 37°C. Broth cultures were incubated on a rotary
shaker at 200-250 rpm to achieve aeration. For selection of transformants, LB medium
was supplemented with 100 µg/ml ampicillin and 50 µg/ml kanamycin as required.
DNA extraction. Chromosomal DNA was extracted from the J strain of M.
hyopneumoniae using a phenol/chloroform method followed by dialysis against TE
buffer as described previously (11). Plasmid DNA was extracted from E. coli using either
the Qiagen mini-prep or midi-prep kit according to the manufacturer’s instructions
(Qiagen, Alameda, Calif.).
Plasmid constructs. Adhesin molecules from two different strains of M.
hyopneumoniae were used to generate poly-histidine fusion proteins of different regions
of the coding sequence. Because UGA codons encode tryptophan in mycoplasmas, they
cause translation problems in E. coli, resulting in premature stops during expression of
cloned sequences. To circumvent this problem, three clones were generated by
amplifying chromosomal DNA from strain J, with PCR primers designed to avoid inframe TGA codons. An additional construct was generated using a clone containing a
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large fragment of the P97 sequence from strain P5722 (19) in which the TGA codons had
been mutagenized to TGGs. This approach was deemed valid because the sequence
differences between these two P97 homologs is less than 4%, with most of the
differences accounted for by variation in the number of R1 and R2 repeats.
The first construct contained the region coding for the N-terminus of the cilium
adhesin (amino acids 106-758 of mutagenized gene sequence) and was referred to as
F1P97. The PCR template for this construct was pISM405 in which the TGA codons had
been converted to TGGs (10). The second construct, referred to as F2P97 (amino acids
768-1069 of J strain sequence), contained the cilium adhesin repeat domains coding for
both R1, the cilium binding epitope, and R2. This gene fragment was further subcloned to
yield two additional constructs referred to as F3P97 (amino acids 768-914 of J strain
sequence) and F4P97 (amino acids 935-1069 of J strain sequence), which contained the R1
and R2 regions, respectively (Fig. 1).
To clone specific sequences, gene fragments were amplified via PCR using Taq
polymerase (Qiagen). Primers used for the amplification of the gene fragments encoding
F1P97, F3P97 and F4P97 were as follows: F1F (5’-GGGGATCCCAAGATCCTGAATAT
ACC) and F1R (5’- GGCTGCAGTTAGGCTGCTTTAAGGAAAAATGC) (underlined
sequences represent BamHI and PstI restriction sites, respectively); F3F (5’- GGGT
CGACAAATTAGACGATAATCTTCAG) and F3R (5’- GGCTGCAGTTAC
TCGCTTTGATGAACTAGTTC) (underlined sequences represent SalI and PstI
restriction sites, respectively); F4F (5’- GGGGATCCCAGGAAGTCAAGGTAACT
AGT) and F4R (5’- GGCTGCAGCCCGGGTTAGGATCACCGGATTTTGAATC)
(underlined sequences represent BamHI and PstI restriction sites, respectively). Primers
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F3F and F4R were used to amplify the gene fragment corresponding to F2P97. The F1P97F4P97 cilium adhesin fragments were digested with the appropriate restriction enzymes
and ligated into linearized pQE-9 with 1 U of T4 DNA ligase (Roche, Basel, Switzerland)
at 10°C overnight. Ligated plasmids were electroporated into E. coli M15 (pREP4) cells
using a BioRad Gene Pulser (Bio-Rad Laboratories, Hercules, Calif.) at 2.5 kV, 25 µFD
and 200 Ω according to the manufacturer’s instructions. All plasmid constructs were
confirmed via DNA sequencing.
Protein expression and purification. All cilium adhesin fragments were expressed
as hexahistidyl fusion proteins and purified by nickel affinity chromatography. Briefly, E.
coli M15 (pREP4) cells were grown to mid-log phase and induced with a final
concentration of isopropyl-β-D-thiogalactopyranoside of 1 mM. Cells were harvested by
centrifugation (4000 x g for 20 min) and then lysed in 8 M urea buffer (8 M urea, 0.01 M
Tris, 0.1 M NaH2PO4; pH 8.0) with gentle rocking for 1 h. Cell debris was pelleted by
centrifugation at 10,000 x g for 30 min. To the supernatant, 0.25 volumes of 50% NiNTA slurry (Qiagen) was added and the solution allowed to mix gently for 1 h. The
solution was loaded onto a glass column and washed twice with 8M urea buffer (pH 6.3)
to remove unbound protein. Bound protein was eluted with low pH urea buffers (pH 5.9
and pH 4.5). Proteins were analysed for purity using sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) then dialysed for 48 h with multiple
buffer changes against phosphate buffered saline (PBS; 10 mM sodium phosphate – 150
mM sodium chloride, pH 7.4)-0.1% SDS or PBS-5% glycerol to remove the urea. The
concentration of the purified proteins was estimated using the Bradford assay (Bio-Rad
Laboratories).
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Production of polyclonal antisera. Antisera to the F1P97-F4P97 adhesin fragments
were generated via primary and secondary intramuscular injections of antigen into New
Zealand white rabbits at two-week intervals. Antigens (approximately 0.5 mg) were
prepared for injection by mixing equal volumes of purified protein (approximately 500
µl) and Freund’s Incomplete Adjuvant (Sigma Aldrich, St. Louis, Missouri). Pre-immune
serum was collected prior to the primary injection and served as control antiserum. A trial
bleed was performed 10-14 days after the secondary injection of antigen and immune
responses to the antigen at this stage were assessed via immunoblotting. Positive sera
were collected via cardiac bleed during which the rabbits were anaesthetized and
euthanized as previously described (32).
Heparin binding assays. For ligand dot blot assays, purified proteins were diluted to
5 µg/ml in PBS. To denature samples, proteins were diluted in electrophoresis sample
buffer (60 mM Tris pH 6.8, 1% SDS, 1% β-mercaptoethanol, 10% glycerol, 0.01%
bromophenol blue) and boiled for 5 min. A 100 µl volume of each sample was spotted
onto a Hybond-C super nitrocellulose membrane (Amersham Pharmacia Biotech,
Uppsala, Sweden) that had been pre-wetted in Tris-buffered saline (TBS; 10 mM Tris,
150 mM sodium chloride; pH 7.4) using a Bio-Dot Microfiltration Apparatus (Bio-Rad
Laboratories). The membrane was blocked with 300 µl per well of blocking solution (1%
bovine serum albumin (BSA) in TBS) and then washed twice under vacuum with 300 µl
per well of TTBS wash solution (0.05% Tween 20 in TBS). The membrane was removed
from the manifold and placed in a dish containing 100 µg/ml biotinylated heparin
(Sigma) diluted in 1% BSA-TTBS. The membrane was incubated for 1 h with gentle
rocking and was then washed 3 x 10 min in TTBS. Streptavidin peroxidase (Roche) was
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diluted 1:3000 in 1% BSA-TTBS and added to the membrane. After 1 h incubation the
blot was washed 3 x 10 min with TTBS. The membrane was equilibrated with 100 mM
Tris (pH 7.6) and developed with 3,3’-diaminobenzidine (Sigma) solution.
For microtitre plate binding assays, 96 well plates (Linbro/Titertek; ICN Biomedicals
Inc., Aurora, Ohio) were coated overnight in a humidified chamber with 0.5 µg per well
purified protein diluted in 100 µl carbonate coating buffer (18 mM NaHCO3, 27 mM
Na2CO3; pH 9.5). Following overnight incubation, the plates were washed 5 times with
PBS-0.2% Tween 20 (200 µl wash solution per well) using an automatic 96PW plate
washer (SLT Labinstruments, Crailsheim, Germany). The wells were blocked with 100
µl of blocking solution (2% skim milk in PBS) for 1 h in a humidified chamber. The
plates were washed 5 times and biotinylated heparin which had been pre-diluted in 1%
skim milk-PBS was added in increasing concentrations to the wells. Final concentrations
of biotinylated heparin were 0, 1, 5, 10, 20, 50, and 100 µg/ml. Aliquots of 100 µl of each
concentration were added to microtitre plate wells; the plates were then incubated for 1 h.
After washing the plates as above, 100 µl of streptavidin-peroxidase (Roche) diluted
1:3000 in 1% skim milk-PBS was added to each well and incubated for 1 h. The plates
were washed and developed using 1 mM 2, 2’-azino-bis (3-ethylbenzothiazoline-6sulfonic acid) substrate (Sigma) in citrate buffer (100 mM citric acid, 200 mM Na2HPO4,
pH 4.2) which had been activated with hydrogen peroxide. Plates were developed with
shaking on a Titramax 1000 microtitre plate shaker (Heidolph, Schwabach, Germany),
and the optical density at 414 nm measured with a Multiskan Ascent plate reader
(Thermo Labsystems, Franklin, Mass.) at 7, 15, 25 and 45 min intervals.
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Microtitre plate assays for determining the specificity of heparin binding, were
performed as above but with serial 2-fold dilutions of biotinylated heparin, beginning at
saturating concentration (100 µg/ml for F1P97 and 50 µg/ml for F2P97), each of which
were pre-mixed with a 50-fold excess of unlabelled heparin prior to addition to the plates.
Competitive binding assays were also performed as above but with the addition of a
1, 5, 10, 20, 30, 40 and 50-fold excess of a range of sulfated polysaccharides. Inhibitors
were pre-mixed with biotinylated heparin immediately prior to addition to the wells and
included unlabelled heparin, fucoidan, mucin and chondroitin sulfate B (Sigma). In all
microtitre plate assays, controls were performed in uncoated wells, wells where no
heparin was added, or wells where no streptavidin-peroxidase was added. Controls which
employed protein-specific antiserum and horseradish peroxidase (HRP)-labelled antirabbit IgG (Chemicon, Temecula, Calif.) were also conducted to ensure that proteins
were adhering to the microtitre plate wells. All experiments were performed in triplicate.
Results were graphed with GraphPad Prism version 4.02 for Windows (GraphPad
Software, San Diego, Calif.; www.graphpad.com) using non-linear regression.

Results
Bioinformatic identification of putative heparin binding motifs. The cilium
adhesin was examined for potential heparin-binding sites within its amino acid sequence
using established criteria (5, 6). In many instances, glycosaminoglycan binding proteins
are reported to contain consensus sequences of two types: XBBXBX and XBBBXXBX,
where B represents a basic residue and X any other amino acid. The F1P97 and F2P97/F3P97
domains of the cilium adhesin each contain one motif that matches the former consensus
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sequence (DKKDKS and DKKVKE respectively) (Fig. 2). Several heparin binding
proteins have been identified that do not contain the consensus sequences but possess
sequences that are relatively rich in basic residues (20, 29). Both F1P97 and F2P97 also
contain relatively large numbers of basic amino acids across the length of their sequences
(Fig. 2).
Heparin binding assays. To determine whether the cilium adhesin fragments bound
to heparin and to assess the importance of their protein conformation in this process,
ligand blots were performed. Standard ligand blots involving the transfer of proteins from
denaturing polyacrylamide gels to PVDF gave only weak or unreliable results (data not
shown). In a dot blot assay, strong and reproducible reactions with biotinylated heparin
were observed for undenatured F1P97 and F2P97, while a weak reaction was observed for
undenatured F4P97 (Fig. 3). Interestingly, the same protein fragments did not show a
strong reaction with heparin when they were denatured prior to blotting, indicating that
protein conformation may play a role in the interaction with heparin.
Quantification of heparin binding by the cilium adhesin domains and determination of
binding affinities was performed by a microtiter plate binding assay. The recombinant
cilium adhesin fragments F1P97-F4P97 were shown to reliably bind to microtitre plates by
interacting with fragment-specific antibodies (data not shown). Experiments were then
performed with increasing amounts of biotinylated heparin up to a saturating
concentration. Fig. 4 indicates the total binding (specific and non-specific) of the cilium
adhesin fragments to heparin. Both F1P97 and F2P97 were found to bind heparin in a dosedependent and saturable manner. In contrast, F3P97 and F4P97 showed low-level, nonsaturable binding, indicating a non-specific interaction.
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To determine whether the binding of F1P97 and F2P97 to heparin was the result of a
specific interaction, binding assays were undertaken in which biotinylated heparin was
added in the presence and absence of a 50-fold concentration of unlabelled heparin.
Binding of heparin to both F1P97 and F2P97 was shown to be highly specific with minimal
non-specific binding observed (Fig. 5A and 5B). Affinity constants were determined
using the specific binding data (total binding minus non-specific binding) and were found
to be 0.27±0.02 µM and 1.89±0.33 µM for F1P97 and F2P97, respectively. These values are
comparable to those derived from replicate experiments.
Inhibition of heparin binding using sulfated polysaccharides. The nature of the
interaction between the cilium adhesin fragments and heparin was further characterised in
competitive binding experiments using the sulfated polysaccharides heparin, fucoidan,
mucin and chondroitin sulfate B. For both F1P97 and F2P97, biotinylated heparin binding
was significantly inhibited by heparin. Furthermore, for both F1P97 and F2P97, fucoidan
and mucin were shown to be strong competitors while chondroitin sulfate B did not
inhibit the interaction of heparin with either adhesin domain (Fig. 6A and 6B). Notably,
both fucoidan and mucin gave stronger inhibition than unlabelled heparin. These results
suggest that both F1P97 and F2P97 are able to bind fucoidan and mucin in addition to
heparin.

Discussion
In order to establish infection, bacterial pathogens must first adhere to and colonize
host epithelia. For many bacteria, the initial site of contact with host tissues is at the level
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of the ECM, therefore the ability to bind components of the ECM is widespread amongst
pathogenic microbes (12, 13, 22, 34). Because of their fastidious nature and obligate
parasitic mode of life, mycoplasmas require particularly efficient mechanisms for
adherence. For M. hyopneumoniae, knowledge about the mechanisms of adhesion to host
tissues is currently confined to the cilium adhesin and its interaction with the cilia of the
porcine respiratory tract (15, 17, 23, 37). No ECM-binding proteins have been identified
in this organism; however, previous studies indicated that binding of the cilium adhesin
to cilia could be inhibited by heparin, providing indirect evidence that the adhesin is able
to bind this molecule (15, 38).
In this study, two non-overlapping regions of the M. hyopneumoniae cilium adhesin,
F1P97 and F2P97, were shown to bind heparin in a dose-dependent, saturable manner.
These results indicate that there are at least two distinct heparin-binding domains within
the adhesin protein. Both of these regions contain clusters of basic amino acids that
match the consensus for glycosaminoglycan-binding motifs (6). One of these protein
regions, F2P97, contains both of the cilium adhesin repeat regions, R1 and R2. The
heparin-binding consensus motif of F2P97 lies within the F3P97 region (Fig. 1A), which
would suggest that F3P97 should also bind heparin. As F3P97 was not shown to bind
heparin in either the ligand blot or microtitre plate assay, it must be concluded that the
heparin binding motif in F2P97 alone was not sufficient to confer binding activity,
indicating that additional sequences are required. F4P97 also failed to show any significant
interaction with heparin in microtitre plate assays indicating that while R1 and R2 are
unable to bind heparin independently, the intact F2P97 fragment (containing both of these
regions) displays heparin-binding activity. The fact that both of the cilium adhesin repeat
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regions are required for heparin binding suggests that this interaction is conformationdependent rather than due to the presence of a specific linear amino acid motif.
Furthermore, the idea that protein conformation plays a role in heparin-binding is
supported by the ligand blot data which demonstrated that undenatured F1P97 and F2P97
were able to bind heparin while the denatured forms were unable to do so.
Alternatively, since 20 amino acids (914-935) were omitted during the construction of
F3P97 and F4P97, it is possible that this sequence may be responsible for the heparinbinding activity observed for F2P97. However, an analysis of this sequence failed to
identify a heparin-binding motif or a basic amino acid density that might facilitate
binding.
Studies on the proteolytic cleavage of the M. hyopneumoniae cilium adhesin have
revealed a complex processing pattern. One major processing event cleaves an Nterminal 22 kDa fragment (P22), generating the “mature” P97 adhesin (10, 37). A second
major event (at position 862 for the J strain) removes a C-terminal 28 kDa fragment
(P28) that separates the cilium binding epitope, R1, from R2. This event generates a
central adhesin fragment that contains R1 and is approximately 66 kDa in size (P66) (10).
Since both R1 and R2 are necessary for the F2P97 fragment of the adhesin to bind heparin,
the cleavage event that generates P28 is likely to impact on the ability of some cilium
adhesin cleavage products to bind glycosaminoglycans. However, this cleavage event
may not have a detrimental effect on the ability of P66 to bind heparin since this is likely
to be conferred by the second heparin binding site found in F1P97. The presence of two
distally located heparin binding sites may allow M. hyopneumoniae to alter its surface
architecture without a corresponding loss in heparin binding activity.
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For some proteins, the ability to bind heparin has been attributed to the presence of
relatively high numbers of evenly spaced basic amino acid residues rather than the
presence of specific linear motifs (20, 29). The positively-charged basic residues are
believed to interact with the exposed, negatively-charged sulfate groups of heparin and
other glycosaminoglycans (5, 6, 20). This may also be true of the cilium adhesin regions
F1P97 and F2P97 which are relatively rich in lysine residues. Further evidence for this type
of interaction can be derived from competitive binding assays. Binding of both F1P97 and
F2P97 to heparin was disrupted by the addition of fucoidan, a highly sulfated fucose
polymer derived from marine algae, but not by chondroitin sulfate B. While not present
in mammalian systems, fucoidan is useful in binding studies due to the high degree of
sulfation of its carbohydrate chains and for this reason is frequently found to be a potent
inhibitor of protein-heparin interactions (14, 24). The strong inhibition of heparin binding
by fucoidan highlights the significance of sulfate groups in this interaction.
Mucin, another highly sulfated compound, was also found to be a powerful inhibitor
in our competitive binding assays. Mucins are abundant in the mucosal secretions lining
various epithelial surfaces (25). Thus, the ability of the cilium adhesin fragments to bind
mucin may in itself be highly significant, since the mucosal layer is often considered the
first defense against pathogens that colonize epithelial surfaces (1). Interactions with the
mucous layer of the respiratory tract would likely precede binding of M. hyopneumoniae
to cilia; therefore binding to mucins may represent an important first step in the
pathogenesis of this organism. Further studies are required to characterize this
interaction.
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The binding affinities (Kd) of both F1P97 (0.27 ± 0.02 µM) and F2P97 (1.89 ± 0.33 µM)
for heparin are within the range reported for other heparin-binding proteins (0.3 nM - 4
µM) such as antithrombin (2), interleukins 2 and 12 (14, 24), clusterin (26) and the
mycobacterial heparin-binding haemagglutinin (29), suggesting that these interactions are
of physiological significance. The ability of the M. hyopneumoniae cilium adhesin to
bind to components of the ECM as well as to cilia indicates that this molecule plays a
multi-functional role in adherence to the porcine respiratory tract. While more
experiments are required to establish the precise role of the adhesin’s interaction with
glycosaminoglycans in vivo, studies of microbial pathogenesis continue to highlight the
importance of binding to heparin and other sulfated polysaccharides in the establishment,
maintenance and dissemination of infection (13, 21, 27, 34). Many pathogens, including
Neisseria, Yersinia, and Staphylococcus species, exploit the widespread ability of host
proteins to bind heparin. By recruiting heparin to their surfaces, these organisms acquire
the ability to interact with a multitude of host molecules and circumvent the need for
individual ligand receptors (13). For organisms such as M. hyopneumoniae, which have
small genomes and therefore a limited repertoire of proteins, the ability to bind
exogenous heparin may significantly increase the potential for host-parasite interactions
at the site of colonization. Host molecules known to interact with heparin include ECM
components, such as fibronectin and vitronectin, and cytokines and inflammatory
mediators (13). Thus, the ability of M. hyopneumoniae to bind heparin may have
important implications with respect to modulation of the host immune system and
inflammatory response in addition to adherence of the pathogen to host tissues.
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Figure legends
Figure 1. (A) Diagrammatic representation of the cilium adhesin gene. Arrows indicate
the location of primers used to amplify DNA fragments coding for F1P97-F4P97. Amino
acid positions corresponding to the N- and C-termini of F1P97-F4P97 are indicated.
Numbers marked with an asterisk (*) indicate positions corresponding to the cilium
adhesin of M. hyopneumoniae strain P5722; all other numbers correspond to the cilium
adhesin M. hyopneumoniae strain J. The F1P97-F4P97 adhesin fragment sizes are
indicated. (B) Sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) showing the
purified, recombinant F1P97-F4P97 cilium adhesin fragments. Lane 1: Prestained protein
molecular weight marker (MBI Fermentas, Hanover, Maryland); band sizes correspond
to 118, 86, 47, 34, 26 and 19kDa, Lane 2: F1P97, Lane 3: F2P97, Lane 4: F3P97, Lane 5:
F4P97. All cilium adhesin fragments run at higher molecular weights than predicted due
to abnormal migration patterns.

Figure 2. Amino acid sequences of F1P97-F4P97. The sequences shown correspond to the
M. hyopneumoniae strains and numbering described in Fig 1A. F3P97 and F4P97 are
indicated by large boxes. Small boxes indicate motifs matching the heparin-binding
consensus sequences. Basic residues are shaded. Tryptophan residues that represent
mutagenised TGG codons are underlined. Repeat regions 1 and 2 (R1 and R2) are
italicized and underscored.

Figure 3. Ligand dot blot of denatured and undenatured cilium adhesin fragments
reacted with (A) biotinylated heparin and (B) amido black. All samples were analysed on
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a single blot. Position 1: undenatured F1P97; position 2: denatured F1P97; position 3:
undenatured F2P97, position 4: denatured F2P97, position 5: undenatured F3P97, position 6:
denatured F3P97, position 7: undenatured F4P97, position 8: denatured F4P97.

Figure 4. Binding of biotinylated heparin to immobilized cilium adhesin domains F1P97
(●), F2P97 (○), F3P97 (■) and F4P97 (□). Increasing concentrations of biotinylated heparin
were added until saturation was reached. Absorbances were read after 45 min incubation
in the presence of substrate. Error bars indicate the standard deviation from the mean for
triplicate readings. Replicate experiments resulted in similar binding curves.

Figure 5. Heparin binding curves for (A) F1P97 and (B) F2P97 showing total binding (●),
non-specific binding (■) and specific binding (○). Total binding was determined using
the standard microtitre plate assay protocol while non-specific binding was determined in
the presence of a 50-fold excess of unlabelled heparin. The specific binding curves were
derived by subtracting the non-specific binding data from the total binding data. Error
bars indicate the standard deviation from the mean for triplicate readings.

Figure 6. Competitive binding assays showing inhibition of heparin binding to (A) F1P97
and (B) F2P97 by various sulfated polysaccharides: unlabelled heparin (●), fucoidan (■),
mucin (○) and chondroitin sulfate B (□). Microtitre plate binding assays were performed
using the standard protocol but with an excess of each inhibitor. Error bars indicate the
standard deviation from the mean for triplicate readings.
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Figure 6A.
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